Article Text

Download PDFPDF
Highlights from the literature

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Some hope for vitiligo

Skin depigmentation causes great anxiety in children and their families. Vitiligo is an autoimmune condition and very hard to treat. Lucina usually ends up referring for cosmetic make up advice. The adult literature is making some progress and suggests there may be hope for the future. Rosmarin D et al (N Engl J Med 2022;387:1445–1455. doi:10.1056/NEJMoa2118828) have recruited to two, double blind, phase 3, controlled trials of ruxolitinib which is a Janus kinase 1 and 2 inhibitor in the form of a topical application. The Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1) and 2 (TRuE-V2) studies enrolled patients from Europe and USA. In 674 subjects of 12 years or older with vitiligo involving less than or equal to 10% skin coverage. Subjects were randomly allocated to apply 1.5% ruxolitinib cream or placebo for 6 months applied two times a day. All subjects then went on to use active treatment through to the end of the year. There were 330 individuals in TRuE-V1 and 344 in TRuE-V2. In TRuE-V1. They used the validated standard Vitiligo Area Scoring Index (F-VASI) and the Vitiligo Noticeability Scale (VNS) as outcome measures. At 6 months, the TRuE-1 active treatment group had …

View Full Text


  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Provenance and peer review Commissioned; internally peer reviewed.